Interleukin-6 (IL-6) Archives - Page 2 of 2

Sanofi and Regeneron Launch Second Kevzara Trial Against COVID-19

Canada, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, France, Germany, Immune Response, Interleukin-6 (IL-6), Italy, Japan, R&D, Rheumatoid Arthritis, Russia, Spain

Regeneron and Sanofi dosed the first patient outside of the United States with the rheumatoid arthritis drug Kevzara as part of a second global clinical trial assessing the medication as a treatment for COVID-19, the disease caused by the novel coronavirus pandemic.

April 1, 2020/by BioSpace

Genentech’s Satralizumab Shows Strong Results in Rare CNS Disorder

Autoimmune Disorders, Clinical Trials, Inflammation, Interleukin-6 (IL-6), Neuromyelitis Optica Spectrum Disorder (NMOSD), Neuromyelitis Optica Spectrum Disorder (NMOSD), R&D, Rare Disorders

Genentech released full data from the company’s pivotal Phase III SAkuraStar trial of satralizumab as a monotherapy for NMOSD.

September 12, 2019/by BioSpace

FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis

Approvals, FDA/Regulatory, Interleukin-6 (IL-6), New Formulations, Systemic Juvenile Idiopathic Arthritis (SJIA)

Roche Group member Genentech announced today that the U.S. FDA approved the subcutaneous formulation of Actemra (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

September 13, 2018/by Business Wire

FDA Approves Actemra for CAR T Cell-Induced CRS

Approvals, Blockbusters, Chimeric Antigen Receptor T Cell Therapy (CART), FDA, FDA/Regulatory, First-of-its kind, Interleukin-6 (IL-6), Oncology, Orphan Drugs, Priority Review

The U.S. FDA approved Genentech’s Actemra (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in patients 2 years of age and older.

August 30, 2017/by Business Wire